Rein Therapeutics Inc (RNTX) - Total Liabilities
Based on the latest financial reports, Rein Therapeutics Inc (RNTX) has total liabilities worth $14.70 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore RNTX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Rein Therapeutics Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Rein Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Rein Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Rein Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fluence Corporation Ltd
AU:FLC
|
Australia | AU$121.17 Million |
|
Professional Computer Technology Ltd
TWO:6270
|
Taiwan | NT$1.19 Billion |
|
Jaya Konstruksi Manggala Pratama
JK:JKON
|
Indonesia | Rp1.12 Trillion |
|
kenturn Nano Tec Co Ltd
TWO:4561
|
Taiwan | NT$859.47 Million |
|
Nature Holdings Co. Ltd.
KQ:298540
|
Korea | ₩283.18 Billion |
|
JMC Electronics Co Ltd
TW:6552
|
Taiwan | NT$1.58 Billion |
|
Sparebank 68 Grader Nord
OL:SB68
|
Norway | Nkr11.17 Billion |
|
Sunsuria Bhd
KLSE:3743
|
Malaysia | RM1.27 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Rein Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Rein Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rein Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rein Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of Rein Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.24 Million | -51.24% |
| 2024-12-31 | $14.85 Million | -85.02% |
| 2023-12-31 | $99.12 Million | +2829.11% |
| 2022-12-31 | $3.38 Million | -26.07% |
| 2021-12-31 | $4.58 Million | +9.52% |
| 2020-12-31 | $4.18 Million | -59.91% |
| 2019-12-31 | $10.43 Million | -2.68% |
| 2018-12-31 | $10.71 Million | +119.01% |
| 2017-12-31 | $4.89 Million | -96.35% |
| 2016-12-31 | $133.83 Million | +33.48% |
| 2015-12-31 | $100.26 Million | -- |
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more